Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released

Jaguar Health, Inc.

Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.
Exchanged all 99.3822 Series J shares for Series L perpetual preferred stock with Streeterville.
Issued 22 Series L shares to Iliad for $550,000 royalty reduction; Series L pays 0%/10%/15% preferred return.
Q1 2025 earnings press released (financial details not provided in filing).
Company will seek stockholder approval to exceed Nasdaq exchange cap for Series L conversions.

item 1.01 item 2.02 item 2.03 item 3.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jaguar Health, Inc.: Filed Series L Certificate of Designation with Delaware Secretary of State, establishing preferences, rights, and limitations of Series L Preferred Stock (effective 2025-05-14).

Change: charter amendment
Effective: 2025-05-14

Exact text from the filing

The preferences, rights, limitations and other matters relating to the Series L Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on May 14, 2025.

View on SEC.gov

25 governance changes filed in the last 30 days. Browse all governance changes →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-120763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.